# AstraZeneca PLC (AZN) Stock Analysis: Exploring an 8.40% Upside Potential

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-azn-stock-analysis-exploring-an-8-40-upside-potential/4121214303
- Published: 2025-09-01T10:11:02+01:00
- Author: Madison Wilson

[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)(
AZN), a titan in the healthcare sector, continues to capture investor attention 
with its robust portfolio and strategic collaborations. Known for its innovation
in drug manufacturing, AstraZeneca is a key player in the global healthcare landscape,
boasting a market capitalization of $247.73 billion. Headquartered in Cambridge,
United Kingdom, the company specializes in the discovery, development, and commercialization
of prescription medicines, catering to a wide range of therapeutic areas including
oncology, cardiovascular, respiratory, and rare diseases.

Currently trading at $79.9 USD, AstraZeneca’s stock offers an intriguing investment
opportunity, particularly with a target price range of $67.00 to $99.00 and an average
target of $86.61. This suggests a potential upside of 8.40%, a figure that could
pique the interest of growth-focused investors. The stock’s 52-week range of $63.20
to $85.75 provides further context to its current valuation, highlighting its resilience
amidst market fluctuations.

Despite lacking a trailing Price-to-Earnings (P/E) ratio, AstraZeneca’s forward 
P/E stands at 15.62, indicating a reasonable valuation compared to industry peers.
The company’s revenue growth of 11.70% underscores its capacity for expansion, further
supported by a solid Return on Equity (ROE) of 19.67%. With an Earnings Per Share(
EPS) of 2.65, AstraZeneca demonstrates a healthy profit-generating ability, albeit
with net income details not disclosed.

AstraZeneca’s financial health is bolstered by a free cash flow of approximately
$8.97 billion, reflecting its strong operational efficiency and capacity to fund
future growth initiatives. The company also delivers a dividend yield of 1.96%, 
with a payout ratio of 58.38%, offering a balanced return for income-seeking investors.

The analyst consensus for AstraZeneca is notably optimistic, with 9 buy ratings,
2 hold ratings, and no sell ratings. This positive sentiment is supported by the
company’s strategic alliances, such as its collaboration with Tempus in oncology
and IonQ, Inc. in quantum-accelerated computational chemistry. These partnerships
not only enhance AstraZeneca’s R&D capabilities but also position it at the forefront
of healthcare innovation.

From a technical standpoint, AstraZeneca’s stock is currently trading above its 
50-day moving average of $73.80 and the 200-day moving average of $70.97, suggesting
a bullish trend. However, the Relative Strength Index (RSI) of 12.89 indicates the
stock is heavily oversold, potentially signaling a buying opportunity for astute
investors.

In the competitive landscape of global pharmaceuticals, AstraZeneca’s strategic 
focus on targeted therapies and innovative treatments sets it apart. Its diverse
product lineup and forward-looking partnerships underscore its commitment to addressing
complex medical challenges worldwide. As AstraZeneca continues to expand its portfolio
and strengthen its market position, investors will be keenly watching for further
developments that could drive future growth and enhance shareholder value.

Share on:
